This story is currently available in anglais only — a translation isn't ready yet.
Isomorphic Labs raises $5bn in one of UK tech's biggest funding rounds
The London AI drug discovery firm spun out of Google DeepMind says the Series C round will fund its push towards first clinical trials

Isomorphic Labs, the London-based AI drug discovery company spun out of Google DeepMind, has raised $5bn (£3.8bn) in what AI minister Kanishka Narayan called one of the biggest Series C rounds in UK tech history.
The oversubscribed round, announced on Tuesday, was co-led by US venture capital firms Greenoaks and Sequoia Capital. Andreessen Horowitz also participated, alongside Alphabet, Thrive Capital, MGX, GV, Capital G, Temasek and the UK government's Sovereign AI Fund.
The company, led by Nobel Prize-winning scientist Sir Demis Hassabis, did not disclose its valuation after the raise. The investment follows reports last month that Isomorphic was seeking a valuation of up to $50bn, compared with roughly $17.5bn previously.
The $5bn injection comes just six months after Isomorphic secured $2.1bn in Series B funding, bringing its total disclosed external funding to approximately $7.7bn.
Narayan said the government's Sovereign AI Fund had made a follow-on investment in the company, backing its continued global growth. He said its work could change how new medicines are discovered and accelerate development of treatments for patients around the world.
Founded in 2021, Isomorphic uses AI to design potential medicines by predicting how molecules interact with biological targets, aiming to reduce the time and cost of drug development. Its proprietary drug design engine, 'IsoDDE', combines AI simulation models to identify and refine potential treatments across different diseases.
The company is developing its own medicines targeting cancer and immune disorders, alongside partnerships with pharmaceutical companies including Eli Lilly, Novartis and Johnson & Johnson.
Despite raising billions, Isomorphic has yet to begin testing its own drug candidates in humans. It remains in late-stage preclinical development, with encouraging early results across its internal oncology and immunology programmes and partnered projects.
The latest funding will support the development of its AI models, expansion of its drug pipeline and construction of global bioengineering infrastructure as it prepares to enter clinical trials.
"Our drug design engine is generating molecules with unprecedented precision and speed," Hassabis said. He said the round would let the company build foundational biology models, deepen its understanding of disease and drive its first therapeutic programmes towards clinical trials.
Sources — how we know this
2 independent sources corroborated this
- PrimaryCity AM
- CorroboratingTechCrunch